Bulletin
Investor Alert

Repligen Corp.

NAS: RGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 22, 2021, 7:40 p.m.

/zigman2/quotes/210324360/composite

$

277.00

Change

+2.05 +0.75%

Volume

Volume 19,914

Quotes are delayed by 20 min

/zigman2/quotes/210324360/composite

Previous close

$ 270.76

$ 274.95

Change

+4.19 +1.55%

Day low

Day high

$267.60

$275.43

Open

52 week low

52 week high

$162.29

$327.32

Open

Company Description

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downs...

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Valuation

P/E Current

247.27

P/E Ratio (with extraordinary items)

156.24

P/E Ratio (without extraordinary items)

172.33

Price to Sales Ratio

28.20

Price to Book Ratio

6.86

Price to Cash Flow Ratio

159.89

Enterprise Value to EBITDA

90.94

Enterprise Value to Sales

26.99

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

324,699.00

Income Per Employee

53,126.00

Receivables Turnover

6.37

Total Asset Turnover

0.22

Liquidity

Current Ratio

2.83

Quick Ratio

2.53

Cash Ratio

2.25

Profitability

Gross Margin

53.06

Operating Margin

22.19

Pretax Margin

16.17

Net Margin

16.36

Return on Assets

3.63

Return on Equity

4.63

Return on Total Capital

5.20

Return on Invested Capital

4.17

Capital Structure

Total Debt to Total Equity

18.01

Total Debt to Total Capital

15.26

Total Debt to Total Assets

14.47

Long-Term Debt to Equity

1.73

Long-Term Debt to Total Capital

1.46

Officers and Executives

Name Age Officer Since Title
Mr. Tony J. Hunt 55 2014 President, Chief Executive Officer & Director
Mr. Jim Bylund - 2020 Senior Vice President-Global Operations & IT
Mr. Jon K. Snodgres 53 2014 Secretary, Chief Financial & Accounting Officer
Mr. Ralf Kuriyel 60 2016 Senior Vice President-Research & Development
Mr. Kola Otitoju - - Senior VP-Strategy & Business Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/14/2021 Karen A. Dawes
Director
27   Disposition at $295.82 per share. 7,987
09/14/2021 Karen A. Dawes
Director
108   Disposition at $295.02 per share. 31,862
09/14/2021 Karen A. Dawes
Director
101   Disposition at $294.06 per share. 29,700
09/14/2021 Karen A. Dawes
Director
25   Disposition at $292.34 per share. 7,308
09/14/2021 Karen A. Dawes
Director
13   Disposition at $290.02 per share. 3,770
09/09/2021 Tony J. Hunt
Chief Executive Officer; Director
8   Disposition at $296.58 per share. 2,372
09/09/2021 Tony J. Hunt
Chief Executive Officer; Director
1,631   Disposition at $296.09 per share. 482,922
09/09/2021 Tony J. Hunt
Chief Executive Officer; Director
14,825   Disposition at $294.9 per share. 4,371,892
09/09/2021 Tony J. Hunt
Chief Executive Officer; Director
8,536   Disposition at $294.22 per share. 2,511,461
09/09/2021 Tony J. Hunt
Chief Executive Officer; Director
25,000   Derivative/Non-derivative trans. at $32.4 per share. 810,000
09/01/2021 Karen A. Dawes
Director
851   Disposition at $285.44 per share. 242,909
09/01/2021 Karen A. Dawes
Director
1,107   Disposition at $284.64 per share. 315,096
09/01/2021 Karen A. Dawes
Director
661   Disposition at $283.56 per share. 187,433
09/01/2021 Karen A. Dawes
Director
405   Disposition at $282.53 per share. 114,424
09/01/2021 Karen A. Dawes
Director
196   Disposition at $281.68 per share. 55,209
09/01/2021 Karen A. Dawes
Director
239   Disposition at $280.27 per share. 66,984
09/01/2021 Christine Gebski
See Remarks
3,377   Disposition at $285.33 per share. 963,559
09/01/2021 Karen A. Dawes
Director
3,459   Derivative/Non-derivative trans. at $38.76 per share. 134,070
08/30/2021 Ralf Kuriyel
Senior VP, R&D
4,001   Disposition at $282.13 per share. 1,128,802
08/18/2021 Karen A. Dawes
Director
40   Disposition at $262.31 per share. 10,492
08/18/2021 Karen A. Dawes
Director
78   Disposition at $260.91 per share. 20,350
08/18/2021 Karen A. Dawes
Director
388   Disposition at $259.93 per share. 100,852
08/18/2021 Karen A. Dawes
Director
634   Disposition at $258.91 per share. 164,148
08/18/2021 Karen A. Dawes
Director
302   Disposition at $257.66 per share. 77,813
08/17/2021 Tony J. Hunt
Chief Executive Officer; Director
1,000   Gift at $0 per share. 0
08/17/2021 Karen A. Dawes
Director
194   Disposition at $256.43 per share. 49,747
08/17/2021 Karen A. Dawes
Director
2,231   Disposition at $255.07 per share. 569,061
08/17/2021 Karen A. Dawes
Director
8,580   Disposition at $254.09 per share. 2,180,092
08/17/2021 Karen A. Dawes
Director
4,665   Disposition at $253.34 per share. 1,181,831
08/17/2021 Karen A. Dawes
Director
920   Disposition at $251.92 per share. 231,766
08/17/2021 Karen A. Dawes
Director
924   Disposition at $251.15 per share. 232,062
08/04/2021 Thomas F. Ryan
Director
780   Disposition at $250.5 per share. 195,390
07/20/2021 Karen A. Dawes
Director
614   Disposition at $203.11 per share. 124,709
07/20/2021 Karen A. Dawes
Director
2,877   Disposition at $202.29 per share. 581,988
07/20/2021 Karen A. Dawes
Director
806   Disposition at $201.37 per share. 162,304
07/20/2021 Karen A. Dawes
Director
288   Disposition at $200.01 per share. 57,602
07/13/2021 Karen A. Dawes
Director
5   Disposition at $204.02 per share. 1,020
07/13/2021 Karen A. Dawes
Director
444   Disposition at $203.09 per share. 90,171
07/13/2021 Karen A. Dawes
Director
630   Disposition at $202.29 per share. 127,442
07/13/2021 Karen A. Dawes
Director
441   Disposition at $201.27 per share. 88,760
07/13/2021 Karen A. Dawes
Director
2,929   Derivative/Non-derivative trans. at $41.19 per share. 120,645
07/13/2021 Karen A. Dawes
Director
2,929   Derivative/Non-derivative trans. at $41.19 per share. 120,645
07/13/2021 Karen A. Dawes
Director
1,520   Disposition at $202.23 per share. 307,389
06/10/2021 Ralf Kuriyel
Senior VP, R&D
6,802   Disposition at $189.19 per share. 1,286,870
06/10/2021 Ralf Kuriyel
Senior VP, R&D
1,045   Derivative/Non-derivative trans. at $86.1 per share. 89,974
06/10/2021 Ralf Kuriyel
Senior VP, R&D
2,557   Derivative/Non-derivative trans. at $59.52 per share. 152,192
/news/latest/company/us/rgen

MarketWatch News on RGEN

  1. Repligen stock price target raised to $335 from $255 at KeyBanc Capital

    6:15 a.m. Sept. 17, 2021

    - Tomi Kilgore

  2. How a 53-Year-Old Growth Fund Takes the Long View

    9:30 p.m. July 30, 2021

    - Barron's Online

  3. Repligen started at overweight with $241 stock price target at KeyBanc Capital

    8:03 a.m. Nov. 10, 2020

    - Tomi Kilgore

  4. Small-Cap ‘Darlings’ Are Perking Up in 2020

    11:47 a.m. Jan. 21, 2020

    - Barron's Online

  5. These 6 stocks in the S&P 1500 have more than doubled in 12 months

    7:28 a.m. July 13, 2019

    - Philip van Doorn

  6. Repligen started at overweight with $42 stock price target at J.P. Morgan

    8:28 a.m. Dec. 5, 2017

    - Tomi Kilgore

  7. Repligen stock fair value estimate raised to $47 from $42 at Janney

    11:26 a.m. June 23, 2017

    - Tomi Kilgore

  8. Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln

    7:01 a.m. June 23, 2017

    - Tomi Kilgore

  9. Repligen's stock halted for news pending

    6:58 a.m. June 23, 2017

    - Tomi Kilgore

  10. Repligen's stock was inactive premarket prior to trading halt

    6:59 a.m. June 23, 2017

    - Tomi Kilgore

  11. Investing From the Ground Up

    12:13 a.m. Sept. 15, 2016

    - Barron's Online

  12. Why Danaher’s Purchase of Pall Means More M&A is on the Way

    11:39 a.m. May 13, 2015

    - Barrons Blogs

  13. Bull trend absorbs soft second-quarter start

    10:41 a.m. April 6, 2015

    - Michael Ashbaugh

  14. These are the most profitable Nasdaq biotech companies

    12:36 p.m. March 2, 2015

    - Philip van Doorn

  15. Loading more headlines...
/news/nonmarketwatch/company/us/rgen

Other News on RGEN

  1. 2 Tricks and a Treat for Gene Therapy Investors

    6:45 a.m. Oct. 18, 2021

    - Motley Fool

  2. Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

    11:43 a.m. Sept. 24, 2021

    - Zacks.com

  3. 3 Unstoppable Healthcare Stocks to Buy With Just $1,000

    7:27 a.m. Sept. 22, 2021

    - Motley Fool

  4. Great Performers That Are Still Great Stocks

    3:11 p.m. Sept. 21, 2021

    - Motley Fool

  5. AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA

    12:07 p.m. Sept. 21, 2021

    - Zacks.com

  6. Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

    10:58 a.m. Sept. 17, 2021

    - Zacks.com

  7. Repligen acquires Avitide in cash and stock deal of $150M

    7:47 a.m. Sept. 16, 2021

    - Seeking Alpha

  8. The Landslide Portfolio

    8:18 p.m. Sept. 14, 2021

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

Repligen Corp.

41 Seyon Street

Building 1

Suite 100

Waltham, Massachusetts 02453

Phone

1 7812500111

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$366.26M

Net Income

$59.93M

2020 Sales Growth

35.5%

Employees

1,128

/news/pressrelease/company/us/rgen

Press Releases on RGEN

  1. Repligen to Report Third Quarter 2021 Financial Results

    7:30 a.m. Oct. 14, 2021

    - GlobeNewswire

  2. Repligen Announces Agreement to Acquire Avitide Inc.

    7:41 a.m. Sept. 16, 2021

    - GlobeNewswire

  3. Chromatography Resin Market Size, Share, Trends, Analysis and Forecast 2027

    7:33 a.m. Aug. 25, 2021

    - Market Insight Reports

  4. Loading more headlines...
Link to MarketWatch's Slice.